Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.7.1.67: 1-phosphatidylinositol 4-kinase

This is an abbreviated version!
For detailed information about 1-phosphatidylinositol 4-kinase, go to the full flat file.

Word Map on EC 2.7.1.67

Reaction

ATP
+
1-phosphatidyl-1D-myo-inositol
=
ADP
 +
1-phosphatidyl-1D-myo-inositol 4-phosphate

Synonyms

1-phosphatidyl-1D-myo-inositol 4-phosphotransferase, 56 kDa type II PtdIns 4-kinase, alpha type II PI 4-kinase, AtPI4KIIIalpha1, AtPI4KIIIbeta1, AtPI4KIIIbeta2, beta type II PI 4-kinase, beta-type phosphatidylinositol 4-kinase, kinase, phosphatidylinositol (phosphorylating), Lsb6, Lsb6p, phosphatidyl-inositol 4-kinase type IIIalpha, phosphatidylinositol 4 kinase, phosphatidylinositol 4 kinase IIIbeta, phosphatidylinositol 4-kinase, phosphatidylinositol 4-kinase beta, phosphatidylinositol 4-kinase beta1, phosphatidylinositol 4-kinase IIalpha, phosphatidylinositol 4-kinase IIbeta, phosphatidylinositol 4-kinase III alpha, phosphatidylinositol 4-kinase IIIalpha, phosphatidylinositol 4-kinase IIIbeta, phosphatidylinositol 4-kinase IIIbeta,, phosphatidylinositol 4-kinase type 2-alpha, phosphatidylinositol 4-kinase type II, phosphatidylinositol 4-kinase type II alpha, phosphatidylinositol 4-kinase type IIalpha, phosphatidylinositol 4-kinase type IIbeta, phosphatidylinositol 4-kinase type-III alpha, phosphatidylinositol kinase, phosphatidylinositol-4-kinase, phosphatidylinositol-4-kinase IIalpha, phosphatidylinositol-4-kinase III beta, phosphatidylinositol-4-kinase type II alpha, phosphatidylinositol-4-kinase type IIalpha, PI 4-kinase, PI 4-kinase type IIalpha, PI kinase, PI-4 kinase, PI4-kinase, PI4K, PI4K beta, PI4K IIalpha, PI4K IIbeta, PI4K IIIbeta, PI4K2, PI4K230, PI4K2A, PI4K55, PI4K92, PI4KA, PI4KB, PI4Kbeta, PI4Kbeta1, PI4Kgamma3, PI4Kgamma5, PI4KII, PI4KIIalpha, PI4KIIbeta, PI4KIII-beta, PI4KIIIalpha, PI4KIIIbeta, Pik1, Pik1p, PIK230, Pik2p, Pik4ca, PIK4IIalpha, PIK4IIbeta, PIK4IIIalpha, PIK4IIIbeta, PIK55, PIKCB, PtdIns 4-kinase, PtdIns 4-kinase beta, PtdIns4KIIalpha, Stt4p, type II phosphatidylinositol 4-kinase, type II phosphatidylinositol kinase, type II phosphoinositide 4-kinase, type II PI 4-kinase enzyme, type II PI4Kalpha, type II PtdIns 4-kinase, type IIalpha phosphatidylinositol 4-kinase, type III alpha phosphatidylinositol 4-kinase, type III phosphatidylinositol 4-kinase alpha, type III phosphatidylinositol 4-kinase beta, type III PI 4-kinase beta, type III PI4K, type III PI4Kbeta, type-II PI4K, type-III phosphatidylinositol 4-kinase beta1, type-III phosphatidylinositol 4-kinase beta2, type-III PI4K

ECTree

     2 Transferases
         2.7 Transferring phosphorus-containing groups
             2.7.1 Phosphotransferases with an alcohol group as acceptor
                2.7.1.67 1-phosphatidylinositol 4-kinase

Inhibitors

Inhibitors on EC 2.7.1.67 - 1-phosphatidylinositol 4-kinase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
(1-((5-(6-chloro-8-(((2-ethylpyridin-4-yl)methyl)amino)-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxyphenyl)sulfonyl)-piperidin-4-yl)methanol
-
(1R)-3-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]cyclopentan-1-ol
-
-
(2-bromo-4,5-dimethoxyphenyl)(6,7-dimethoxyisoquinolin-1-yl)methanone
-
about 80% residual activity at 0.01 mM
(3-aminopyrrolidin-1-yl)(4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]phenyl)methanone
-
-
(3R)-1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]pyrrolidin-3-ol
(4-[3-[4-(methanesulfonyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)(3-hydroxypyrrolidin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)[(3R)-3-hydroxypyrrolidin-1-yl]methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)[(3S)-3-hydroxypyrrolidin-1-yl]methanone
-
-
(4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[6-[3-(methanesulfonyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl)(piperazin-1-yl)methanone
-
-
1,10-phenanthroline-5,6-dione
-
about 35% residual activity at 0.01 mM
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
about 65% residual activity at 0.01 mM
1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]piperidin-4-ol
1-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]-2-methylpropan-1-one
-
16% residual activity at 0.01 mM
1-[5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonyl]piperidin-4-ol
-
2'(3')-O-(2,4,6-Trinitrophenyl)ATP
-
-
2'-dATP
-
-
2,3-Dihydroxybenzaldehyde
-
-
2-(3-chlorophenyl)-9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
67% residual activity at 0.01 mM
2-(4-methylpiperazin-1-yl)-8-(pyridin-4-yl)-1,5-naphthyridine
2-([3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]sulfonyl)ethanol
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenylketone oxime
-
i.e. enviroxime, inhibitor of the in vitro replication of rhinoviruses and enteroviruses, inhibits hepatitis C virus subgenomic replicon replication
2-ethoxy-6'-methoxy-5-[4-(methylsulfonyl)phenyl]-3,3'-bipyridine
-
-
2-fluoro-5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
2-iodo-6'-methoxy-5-[4-(methylsulfonyl)phenyl]-3,3'-bipyridine
-
-
2-[3-(benzylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-(methylsulfonyl)phenyl]-8-(piperazin-1-yl)-1,5-naphthyridine
2-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-(phenylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(piperidine-1-sulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-[(3R,5S)-3,5-dimethylpiperazine-1-sulfonyl]phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]pyridine
-
about 18% residual activity at 0.01 mM
2-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
3'-dATP
-
-
3-(1-methyl-1H-benzimidazol-5-yl)-6-[3-(propane-2-sulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(morpholin-4-yl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine
3-(3,4-dimethoxyphenyl)-5-methyl-N-[2-(morpholin-4-yl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine
-
31% residual activity at 0.01 mM
3-(3,4-dimethoxyphenyl)-N-[2-(morpholin-4-yl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine
-
41% residual activity at 0.01 mM
3-(4-methylphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
about 55% residual activity at 0.01 mM
3-(6-chloro-2-methyl-8-[[(2-methylpyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-2-methyl-8-[[(pyridin-3-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-2-methyl-8-[[(pyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-methoxypyridin-3-yl)-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]pyrazin-2-amine
-
-
3-(6-methoxypyridin-3-yl)-5-[4-(methylsulfonyl)phenyl]pyrazin-2-amine
-
-
3-(6-methoxypyridin-3-yl)-5-[4-(trifluoromethoxy)phenyl]pyrazin-2-amine
-
-
3-(8-phenyl-1,5-naphthyridin-2-yl)benzenesulfonamide
3-[4-(methylsulfonyl)phenyl]-6-[2-(trifluoromethyl)pyridin-4-yl]imidazo[1,2-b]pyridazine
-
-
3-[4-(methylsulfonyl)phenyl]-6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine
-
-
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(4-benzylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(6-methylpyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]aniline
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-[4-(trifluoromethyl)phenyl]-1,5-naphthyridin-2-yl]benzenesulfonamide
4-(quinoxalin-2-yl)phenyl furan-2-carboxylate
-
about 75% residual activity at 0.01 mM
4-fluoro-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]benzoic acid
-
-
4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
4-[9-(3,4-dimethoxyphenyl)-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-8-yl]benzonitrile
-
97% residual activity at 0.01 mM
4-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]benzonitrile
-
97% residual activity at 0.01 mM
4-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenol
-
18% residual activity at 0.01 mM
5'-AMP
-
0.5 mM, 10% inhibition
5,5'-dithiobis(2-nitrobenzoate)
-
0.03 mM, 10 min, 95% inhibition
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N,N-dimethylbenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(2-methoxyethyl)benzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(prop-2-en-1-yl)benzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonyl chloride
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(1-hydroxybutan-2-yl)-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(2-hydroxyethyl)-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-cyclopropyl-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-[2-(dimethylamino)ethyl]-2-methoxybenzene-1-sulfonamide
-
5-[4-(methylsulfonyl)phenyl]-3-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-amine
-
-
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
5-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-(4-cyanophenyl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-[(2-acetamidoethyl)amino]-6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl]-2-methoxybenzene-1-sulfonyl chloride
-
5-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
6-(3-methylphenyl)-3-(6-methylpyridin-3-yl)imidazo[1,2-b]pyridazine
-
-
6-chloro-3-iodo-2-methyl-N-((2-methylpyridin-4-yl)methyl)-imidazo[1,2-b]pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-2-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-3-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-N-((2-ethylpyr idin-4-yl)methyl)-3-iodo-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-(4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(1H-pyrazole-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(morpholine-4-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(piperidine-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridine
-
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyrimidine
-
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
6-[4-(cyclopropylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
7-(3,4-dimethoxyphenyl)-N-[2-(morpholin-4-yl)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
74% residual activity at 0.01 mM
8-(cyclohex-3-en-1-yl)-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
75% residual activity at 0.01 mM
8-(pyridin-4-yl)-2-[3-(pyrrolidin-1-ylsulfonyl)phenyl]-1,5-naphthyridine
8-(pyridin-4-yl)-2-[5-(trifluoromethyl)pyridin-3-yl]-1,5-naphthyridine
8-bromo-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
17% residual activity at 0.01 mM
8-bromo-ATP
8-cyclohexyl-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
79% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2,8-dimethyl-N-[2-(morpholin-4-yl)ethyl]-5,9-dihydro-4H-purin-6-amine
-
14% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-(4-fluorophenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
66% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-ethynyl-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
18% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-iodo-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
33% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methoxy-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
15% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(3-phenylprop-1-yn-1-yl)-9H-purin-6-amine
-
96% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(propan-2-yl)-9H-purin-6-amine
-
65% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(thiophen-3-yl)-9H-purin-6-amine
-
94% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(trifluoromethyl)-9H-purin-6-amine
-
99% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
26% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-(4-fluorophenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
78% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-iodo-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
38% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methoxy-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
86% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purine-2-carbonitrile
-
24% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(3-phenylprop-1-yn-1-yl)-9H-purin-6-amine
-
58% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(pyridin-3-yl)-9H-purin-6-amine
-
36% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(thiophen-3-yl)-9H-purin-6-amine
-
46% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
13% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N6-[2-(morpholin-4-yl)ethyl]-9H-purine-2,6-diamine
-
25% residual activity at 0.01 mM
adenosine
amyloid beta
-
amino acids 1-42, inhibits type II phosphatidylinositol 4-kinase and enhances glutamate toxicity
-
amyloid beta protein
-
pathophysiological concentrations of amyloid beta proteins directly inhibit. Abeta25-35 inhibits in a non-competitive manner. Inhibition by 10 nM Abeta25-35 is reversible
-
amyloid beta protein 2-42
-
10 nM
-
amyloid beta protein 25-35
-
10 nM, 78% residual activity
-
arachidonic acid
-
0.5 mg/ml, 91.3% inhibition of mPIK-III
artesunate
ATPgammaS
BQR695
BRD73842
Caffeine
-
6.5 mM, 18% inhibition
cetyltrimethylammonium bromide
-
-
Chloroquine
cholesterol
-
cholesterol sensitivity of PI4KIIalpha
Co2+
-
-
Cpd 6
-
-
-
Cu2+
-
0.25 mM CuCl2, complete inhibition
Cutsum
-
above 2% v/v
-
deoxycholate
Fe2+
-
-
Formycin A
-
-
GMP
-
1 mM, 20% inhibition
guanosine
-
1 mM, 50% inhibition
HgCl2
-
5 mM, complete inhibition
inosithin
-
a commercial preparation of ethanol-insoluble phospholipids from soybean; at high concentration
iodoacetate
-
0.1 mM, complete loss of activity
KCl
-
slight inhibition
KDU691
La3+
-
0.2 mM, 78% inhibition
Lubrol Px
-
1%, 72% inhibition
Ly-294002
-
IC50: 0.05-0.1 mM; IC50: 0.1 mM
LY294002
MDL-860
-
irreversible inhibition. MDL-860 only affects in vivo isoform PI4KB activity
MES
-
IC50: 4 mM
methyl N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophanate
-
-
MgADP-
-
IC50: 0.5 mM
MMV390048
N'-(4-methoxybenzoyl)pyridine-2-carbohydrazide
-
about 20% residual activity at 0.01 mM
N'-[(4-methoxybenzoyl)oxy]pyridine-2-carboximidamide
-
about 30% residual activity at 0.01 mM
N,N-dimethyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-(1H-benzimidazol-2-yl)-2-methoxybenzamide
-
about 65% residual activity at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetamide
-
about 40% residual activity at 0.01 mM
N-(2-((3-(3-((1H-pyrazol-1-yl)sulfonyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((3-(3-(N-(4-aminocyclohexyl)sulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((3-(3-(N-allylsulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N,N-dimethylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N-(1-hydroxybutan-2-yl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(3-(N-(2-(dimethylamino)ethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N-(2-hydroxyethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(3-(N-cyclopropylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(N-(2-methoxyethyl)sulfamoyl)-phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(N-methyl-N-(2-(methylamino)-ethyl)sulfamoyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(piperidin-1-ylsulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxyphenyl)-2-methylimidazo[1,2-b]-pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
-
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-(3-aminopropyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-(3-hydroxypropyl)-4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-(4-aminocyclohexyl)-5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonamide
-
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
N-(4-cyanophenyl)-N-methyl-3-[4-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
-
KAI407
N-(5-[4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl]-4-methyl-1,3-thiazol-2-yl)acetamide
-
i.e. PIK93, a phenylthiazole
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-cyclopropyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-[(2S)-1-hydroxypropan-2-yl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-[(oxetan-3-yl)methyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-(dimethylamino)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
N-[2-(morpholin-4-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-(piperidin-1-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
-
N-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
N-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]acetamide
-
14% residual activity at 0.01 mM
N-[5-[4-(dimethylamino)phenyl]-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]pyridine-2-carboxamide
-
about 95% residual activity at 0.01 mM
N-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]methanesulfonamide
N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophan
-
about 20% residual activity at 0.01 mM
N6-dimethylamine-adenosine 5'-triphosphate
Ni2+
-
-
NVP-BGT226
complete inhibition at 0.01 mM
orobol
-
-
PAO
-
inhibitor of type III PI4Ks, with greater specificity for PI4KIIIalpha than for PI4KIIIbeta
Phenylarsine oxide
phosphate
-
20 mM, 50% inhibition
phosphatidic acid
-
slight
phosphatidylcholine
phosphatidylethanolamine
phosphatidylglycerol
phosphatidylinositol 4,5-bisphosphate
phosphatidylinositol 4-phosphate
phosphatidylserine
PIK93
propan-2-yl N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophanate
-
-
quercetin
resveratrol
inhibition of PtdIns 4-kinase activity by resveratrol/phenylarsine oxide reduces Jurkat cell adhesion to matrigel/fibronectin coated surfaces
SDS
-
0.05%, complete
sodium cholate
-
inhibits activity of both mPIK-I and mPIK-III
sodium deoxycholate
-
-
Sodium mersalyl
-
0.1 mM, 78% inhibition
T-00127-HEV1
tert-butyl N-[[8-(2-chlorophenyl)-4,5-dihydro[1,3]thiazolo[4,5-h]quinazolin-2-yl]carbamoyl]-beta-alaninate
-
i.e. Inhibitor A
theophylline
-
2 mM, 21% inhibition
Toyocamycin
-
IC50 is 0.0033 mg/ml
Triton X-100
Wortmannin
[(3R)-3-aminopyrrolidin-1-yl](4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)methanone
-
-
[(3S)-3-aminopyrrolidin-1-yl](4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)methanone
-
-
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
[9-(3,4-dimethoxyphenyl)-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-8-yl]methanol
-
62% residual activity at 0.01 mM
additional information
-